Ticagrelor with or without aspirin in high-risk patients with anaemia undergoing percutaneous coronary intervention: a subgroup analysis of the TWILIGHT trial
Primary result · BARC 2, 3, or 5 bleeding, anaemic patientsResult — go to the resultHazard ratio 0.60 95% CI 0.41–0.88Authors' conclusion
In high-risk patients undergoing PCI, ticagrelor monotherapy after 3 months of ticagrelor-based dual antiplatelet therapy was associated with a reduced risk of clinically relevant bleeding without any increase in ischaemic events irrespective of anaemia status
Study context
- Population
- High-risk patients undergoing percutaneous coronary intervention (PCI) with anaemia (haemoglobin <13 g/dL men, <12 g/dL women)1,329 (19.5%) with anaemia
- Participants
- 6,828 patients
- Comparison
- Ticagrelor monotherapy vs Ticagrelor plus aspirin
- Primary endpoint
- Bleeding Academic Research Consortium (BARC) 2, 3, or 5 bleeding
- Follow-up
- 1 year
Methodological detailssubgroup analysis, placebo-controlled
- Subgroup analysis
- Placebo-controlled
Primary result
BARC 2, 3, or 5 bleeding, anaemic patients
Hazard ratio
0.60
95% CI 0.41–0.88
P = 0.009
By group
Ticagrelor monotherapy vs Ticagrelor plus aspirin
HR 0.60 (95% CI 0.41–0.88); P = 0.009
As reported in the abstract
Secondary outcomes
| Outcome | Ticagrelor monotherapy | Ticagrelor plus aspirin | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| Death, MI or stroke (key secondary), anaemic patients | 5.2% | 4.8% | 1.07 (0.66–1.74) | P = 0.779 | |
| 0.512Hazard ratio (log scale) |
- Death, MI or stroke (key secondary), anaemic patients: consistent in patients without anaemia (interaction P 0.835)
Original publication
Ticagrelor with or without aspirin in high-risk patients with anaemia undergoing percutaneous coronary intervention: a subgroup analysis of the TWILIGHT trial. Eur Heart J Cardiovasc Pharmacother. Published 17 January 2023. doi:10.
Summarised from the published abstract; every number is checked against it